One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to AOD-9604 in Singapore. US research-market identity with a failed oral obesity program and no FDA-approved drug.

Current source route

AOD-9604 in Singapore

Direct answer / Singapore

Can you buy AOD-9604 in Singapore?

US research-market identity with a failed oral obesity program and no FDA-approved drug

AOD-9604 reached controlled human studies, but the largest oral obesity trial did not show a statistically significant weight-loss difference and the sponsor terminated development for obesity. FDA states that neither AOD-9604 free base nor acetate is a component of an approved drug. Current seller-labelled 5 mg research vials do not inherit the identity, route, formulation, manufacturing record, or monitoring of the historical trial products.

  1. 01
    Resolve the nameResearch price board
  2. 02
    Check SingaporeResearch price board
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordUS research-market identity with a failed oral obesity program and no FDA-approved drug

What AOD-9604 resolves to

AOD-9604 reached controlled human studies, but the largest oral obesity trial did not show a statistically significant weight-loss difference and the sponsor terminated development for obesity. FDA states that neither AOD-9604 free base nor acetate is a component of an approved drug. Current seller-labelled 5 mg research vials do not inherit the identity, route, formulation, manufacturing record, or monitoring of the historical trial products.

Evidence lane
Research price board
Current record
3 of 4 rows in stock
Checked
Jul 23, 2026
AOD 9604AOD9604Tyr-hGH 177-191
Destination recordHSA product and e-pharmacy checks

What Singapore still has to prove

A Singapore guide to checking peptide-related offers through HSA's therapeutic-product register, licensed dealer and retail-pharmacy searches, and e-pharmacy requirements.

Comparison mode
SGD / HSA product, dealer, and pharmacy records
Price coverage
No qualified Singapore seller table
Guide updated
July 18, 2026
Evidence coverageRouting records only

No compound-specific official record is attached to this exact pairing yet. That is an evidence gap, not proof of approval, prohibition, availability, or absence. Use the country guide and official product and seller routes to verify the exact offer.

Open the full country check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail